Let your mob (one of the minnows in the IF sector) have him .... how's the $2 predictions you made for them going considering they didn't even reach $1 after FDA approval ... LMAO
A2M have made a smart strategic move in this instance by restricting his stock IMO and given there has been no downgrade to the upcoming financials then the no sales through this self proclaimed guru of daigou since March doesn't seem to be worrying the new CEO .... if Mr Zhang wants to miss out on any A2M profits in the future, then I guess that is his choice
.... and as for the USA market, at least A2M won't have to do an opportunistic CR on the back of the uptick in share price when (IF) they receive an FDA approval
A2M Price at posting:
$4.90 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)